How many years can you live taking Crizotinib/Xalkori? Comprehensive analysis of efficacy and survival

As a targeted therapy, Crizotinib is mainly used to treat patients with ALK-positive or ROS1-positive metastatic non-small cell lung cancer (NSCLC). Its efficacy and impact on survival have been verified in clinical studies. Especially in lung cancer patients with these specific gene mutations, crizotinib has demonstrated significant anti-tumor effects and significantly prolonged patient survival.

In clinical trials for the treatment ofALK-positive non-small cell lung cancer, crizotinib has shown excellent efficacy. According to the results of some large clinical studies, progression-free survival (PFS) of patients with ALK-positive non-small cell lung cancer treated with crizotinib was significantly improved, and the patient's overall response rate (ORR) was also higher. For example, in a study called PROFILE 1007, crizotinib significantly improved the progression-free survival of patients compared with traditional chemotherapy. The PFS of the patients in the study was 7.7 months, compared with 3.0 months in the chemotherapy group.

For the evaluation of survival, the application of crizotinib also had a positive impact. In a several-year follow-up study, ALK-positive patients had improved overall survival (OS) after treatment with crizotinib. Although the survival period of each patient will vary due to individual differences in cancer and diversity of treatments, in most clinical studies, patients treated with crizotinib have shown higher survival rates and good drug resistance in terms of long-term efficacy, especially in patients diagnosed early and actively treated.

Crizotinib effectively controls the proliferation of cancer cells by targetingALK or ROS1 mutations, thereby delaying the progression of the disease. For patients with ALK-positive or ROS1-positive metastatic lung cancer, crizotinib provides a more effective treatment option compared with traditional treatments. By targeting specific mutations in ALK and ROS1 rearrangements, crizotinib can precisely intervene in the growth signals of tumor cells, allowing patients to maintain a better quality of life during treatment and effectively extend survival.

Reference materials:https://go.drugbank.com/drugs/DB08865